RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
-7.04%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$4.74B
AUM Growth
+$4.74B
(-9.8%)
Cap. Flow
+$299M
Cap. Flow
% of AUM
6.3%
Top 10 Holdings %
Top 10 Hldgs %
55.75%
Holding
72
New
10
Increased
16
Reduced
6
Closed
5
Top Buys
| 1 |
SAGE
Sage Therapeutics
SAGE
|
$106M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$100M |
| 3 |
Taysha Gene Therapies
TSHA
|
$53.4M |
| 4 |
Apogee Therapeutics
APGE
|
$45.6M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$37.4M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$103M |
| 2 |
Intuitive Surgical
ISRG
|
$58.1M |
| 3 |
Illumina
ILMN
|
$25.8M |
| 4 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
$24.8M |
| 5 |
Maravai LifeSciences
MRVI
|
$19.1M |
Sector Composition
| 1 | Healthcare | 99.97% |
| 2 | Financials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Rocket Pharmaceuticals
RCKT
$354M
| $362M | 7.65% | 17,687,772 | – | – |
|
2
Immunocore
IMCR
$1.62B
| $316M | 6.68% | 6,096,387 +66,754 | +1% | +$3.46M |
|
3
Axsome Therapeutics
AXSM
$6.05B
| $314M | 6.62% | 4,489,596 +205,319 | +5% | +$14.3M |
|
4
Alnylam Pharmaceuticals
ALNY
$58.5B
| $298M | 6.29% | 1,683,362 | – | – |
|
|
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $295M | 6.22% | 6,768,514 +2,295,529 | +51% | +$100M |
|
6
argenx
ARGX
$43.6B
| $249M | 5.26% | 507,195 +25,000 | +5% | +$12.3M |
|
|
7
Acadia Pharmaceuticals
ACAD
$4.38B
| $241M | 5.09% | 11,576,537 +1,793,288 | +18% | +$37.4M |
|
8
Bruker
BRKR
$5.16B
| $211M | 4.45% | 3,381,703 +422,100 | +14% | +$26.3M |
|
9
Ultragenyx Pharmaceutical
RARE
$2.89B
| $193M | 4.07% | 5,405,089 | – | – |
|
10
Penumbra
PEN
$10.6B
| $163M | 3.44% | 673,371 | – | – |
|
11
PTC Therapeutics
PTCT
$3.92B
| $162M | 3.42% | 7,235,196 | – | – |
|
12
Thermo Fisher Scientific
TMO
$186B
| $147M | 3.1% | 290,334 | – | – |
|
13
Masimo
MASI
$7.59B
| $132M | 2.78% | 1,501,493 | – | – |
|
14
Establishment Labs
ESTA
$1.2B
| $122M | 2.58% | 2,494,138 | – | – |
|
15
Natera
NTRA
$23.1B
| $117M | 2.48% | 2,651,783 +40,000 | +2% | +$1.77M |
|
16
Vericel Corp
VCEL
$1.83B
| $110M | 2.33% | 3,291,873 | – | – |
|
|
SAGE
17
DELISTED
Sage Therapeutics
SAGE
| $106M | 2.24% | +5,149,482 | New | +$106M |
|
18
Celldex Therapeutics
CLDX
$1.47B
| $95.3M | 2.01% | 3,463,201 | – | – |
|
19
Protagonist Therapeutics
PTGX
$3.67B
| $90.3M | 1.91% | 5,415,514 | – | – |
|
20
Cytokinetics
CYTK
$4.23B
| $75.8M | 1.6% | 2,574,198 | – | – |
|
|
AVDL
21
Avadel Pharmaceuticals
AVDL
$1.43B
| $73.5M | 1.55% | 7,136,415 +325,774 | +5% | +$3.36M |
|
22
10x Genomics
TXG
$1.74B
| $62.7M | 1.32% | 1,519,956 +57,000 | +4% | +$2.35M |
|
|
23
Taysha Gene Therapies
TSHA
$797M
| $53.4M | 1.13% | +16,893,185 | New | +$53.4M |
|
24
Tarsus Pharmaceuticals
TARS
$2.47B
| $51.2M | 1.08% | 2,880,701 +332,576 | +13% | +$5.91M |
|
25
Orchestra BioMed
OBIO
$147M
| $49M | 1.03% | 5,620,640 | – | – |
|